AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21742583 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release formulation of ciprofloxacin (500 mg once daily)
Number of subjects: 36
Study 21742583 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release formulation of ciprofloxacin (250 mg twice daily)
Number of subjects: 36
Study 18728933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine 3.125 mg
Number of subjects: 17
Study 18728933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine 6.250 mg
Number of subjects: 17
Study 18728933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine 9.375 mg
Number of subjects: 17
Study 18728933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16685123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous glycaemic control (RC) with i.v. insulin and intravenous crystalloid
Number of subjects: 25
Study 16685123 — intervention group
Group type: COMPARATOR
Intervention: Standard management (SM) with intravenous crystalloid
Number of subjects: 25
Study 15300734 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-on (50 Hz magnetic field)
Number of subjects: 15
Study 15300734 — intervention group
Group type: COMPARATOR
Intervention: MF-off (control)
Number of subjects: 15
Study 11750293 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient clinic treatment
Number of subjects: 22
Study 11750293 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial level of depression, disability, pain, beliefs about the consequences of arthritis, coping strategies
Number of subjects: 22
Study 9155828 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 10
Study 9155828 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 8292466 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (mean final dose 6.8 mg/day)
Number of subjects: 4621
Study 8292466 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 4621
Study 30660609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 125
Study 30660609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (Nivolumab 3 mg/kg every 2 weeks + Ipilimumab 1 mg/kg every 6 weeks)
Number of subjects: 125
Study 28862315 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month progressive home-based training with regular booster sessions (exercise group, n=48)
Number of subjects: 98
Study 28862315 — intervention group
Group type: COMPARATOR
Intervention: Usual care (single session of physiotherapy instruction, usual care group, n=50)
Number of subjects: 98
Study 25980706 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Cardiac Rehabilitation Program (vCRP)
Number of subjects: 78
Study 25980706 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 78
Study 23208876 — intervention group
Group type: EXPERIMENTAL
Intervention: One mass azithromycin distribution
Number of subjects: 24
Study 23208876 — intervention group
Group type: COMPARATOR
Intervention: Two mass azithromycin distributions
Number of subjects: 24
Study 21663652 — intervention group
Group type: EXPERIMENTAL
Intervention: CBPR walking intervention with social support walking groups, pedometer diary self-monitoring, monthly diet and physical activity education sessions, and individualized motivational interviewing sessions.
Number of subjects: 269
Study 18761593 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 2784
Study 18761593 — intervention group
Group type: COMPARATOR
Intervention: Delayed circumcision (control group)
Number of subjects: 2784
Study 16390567 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline 0.9% (Group I, n = 20)
Number of subjects: 60
Study 16390567 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 30 mg kg(‐1) bolus + 10 mg kg(‐1) h(‐1) continuous infusion (Group II, n = 20)
Number of subjects: 60
Study 16390567 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 50 mg kg(‐1) bolus + 10 mg kg(‐1) h(‐1) continuous infusion (Group III, n = 20)
Number of subjects: 60
Study 14618196 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (0.5 to 2 ng/kg/min over 6 hours)
Number of subjects: 16
Study 14618196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 10831007 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI (1.0 mg inhaled flunisolide)
Number of subjects: 24
Study 10831007 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-S (1.0 mg inhaled flunisolide with a spacer device)
Number of subjects: 24
Study 10831007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration (1.0 mg of flunisolide with 240 mL of water)
Number of subjects: 24
Study 10831007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (1.0 mg flunisolide by IV push)
Number of subjects: 24
Study 9238407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell voltage duration product adjusted for body mass index and age
Number of subjects: 3351
Study 9238407 — intervention group
Group type: COMPARATOR
Intervention: Original ECG LVH criteria
Number of subjects: 3351
Study 9238407 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment algorithms for lean versus obese and normotensive versus hypertensive
Number of subjects: 3351
Study 1425884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine SR 40 mg b.i.d. for 3 months
Number of subjects: 18
Study 1425884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1425884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg (acute treatment)
Number of subjects: 18
Study 1425884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with Nicardipine SR
Number of subjects: 18
Study 6484101 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A/cardiac counseling
Number of subjects: 1012
Study 6484101 — intervention group
Group type: COMPARATOR
Intervention: Cardiac counseling alone
Number of subjects: 1012
Study 6484101 — intervention group
Group type: COMPARATOR
Intervention: Nonrandom comparison section
Number of subjects: 1012
Study 31354158 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (low-dose)
Number of subjects: 3884
Study 31354158 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 3884
Study 29590422 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacologic approaches for pain management (e.g., tai chi)
Number of subjects: 36
Study 29590422 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with provider about complementary approaches
Number of subjects: 36
Study 29590422 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination
Number of subjects: 36
Study 29590422 — intervention group
Group type: EXPERIMENTAL
Intervention: Veteran expectations about pain experience
Number of subjects: 36
Study 29590422 — intervention group
Group type: EXPERIMENTAL
Intervention: Veteran knowledge and beliefs about complementary approaches
Number of subjects: 36
Study 29590422 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to non-pharmacologic treatments
Number of subjects: 36
Study 26946728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 60
Study 26946728 — intervention group
Group type: COMPARATOR
Intervention: TDP
Number of subjects: 60
Study 25083928 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1 mA for 15 minutes
Number of subjects: 16
Study 25083928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS at 1 mA for 15 minutes
Number of subjects: 16
Study 25083928 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 25083928 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 16
Study 23265076 — intervention group
Group type: EXPERIMENTAL
Intervention: Group diabetes education programme (4 sessions delivered by a health promotion officer)
Number of subjects: 1570
Study 23265076 — intervention group
Group type: COMPARATOR
Intervention: Usual care (ad hoc advice during consultations and occasional educational talks)
Number of subjects: 1570
Study 23265076 — intervention group
Group type: EXPERIMENTAL
Intervention: Group diabetes education programme
Number of subjects: 1570
Study 23265076 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1570
Study 20301996 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of vancomycin (15 mg/kg loading dose for 1 h followed by 30 mg/kg continuous infusion over 24 h for 48 h)
Number of subjects: 12
Study 20301996 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of vancomycin (15 mg/kg for 1 h every 12 h for 48 h)
Number of subjects: 12
Study 20301996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both continuous and intermittent infusion of vancomycin
Number of subjects: 12
Study 18416216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced prime extracorporeal circuit and vacuum‐assisted venous drainage (VAVD)
Number of subjects: 40
Study 18416216 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB with full prime volume (control group)
Number of subjects: 40
Study 14691416 — intervention group
Group type: EXPERIMENTAL
Intervention: Private transportation
Number of subjects: 2388
Study 14691416 — intervention group
Group type: COMPARATOR
Intervention: Calling 9-1-1 (EMS)
Number of subjects: 2388
Study 14691416 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS
Number of subjects: 2388
Study 14691416 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision to seek care to thrombolytic therapy (EMS)
Number of subjects: 2388
Study 12530751 — intervention group
Group type: EXPERIMENTAL
Intervention: Euclidean regression analyses
Number of subjects: 0
Study 12530751 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative hypothesis
Number of subjects: 0
Study 12530751 — intervention group
Group type: EXPERIMENTAL
Intervention: Null hypothesis
Number of subjects: 0
Study 9844218 — intervention group
Group type: COMPARATOR
Intervention: TN‐PAP‐ (29 subjects)
Number of subjects: 100
Study 9844218 — intervention group
Group type: EXPERIMENTAL
Intervention: TN‐PAP+ (25 subjects)
Number of subjects: 100
Study 9844218 — intervention group
Group type: EXPERIMENTAL
Intervention: TN+ PAP‐ (21 subjects)
Number of subjects: 100
Study 9844218 — intervention group
Group type: EXPERIMENTAL
Intervention: TN+ PAP+ (25 subjects)
Number of subjects: 100
Study 9844218 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 100
Study 7978185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 7978185 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study 2554440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 10
Study 2554440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 8 mg
Number of subjects: 10
Study 2554440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 12 mg
Number of subjects: 10
Study 2554440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 5354874 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased intestinal absorption of calcium; possible alteration in renal tubular handling of calcium.
Number of subjects: 6
Study 30977845 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil-9 (licensed prophylactic HPV vaccine)
Number of subjects: 345
Study 30977845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 30977845 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil-9
Number of subjects: 345
Study 28937021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg plus amoxicillin 750 mg (4 times/day for 14 days)
Number of subjects: 263
Study 28937021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg plus amoxicillin 750 mg (4 times/day for 14 days)
Number of subjects: 263
Study 28937021 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple regimen (rabeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, clarithromycin 500 mg, 2 times/day for 14 days)
Number of subjects: 263
Study 26031566 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 637
Study 26031566 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 637
Study 26031566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 23770332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal fractional-dose IPV (ID-JI-0.1)
Number of subjects: 125
Study 23770332 — intervention group
Group type: COMPARATOR
Intervention: Full-dose intramuscular needle (IM-NS-0.5)
Number of subjects: 125
Study 23770332 — intervention group
Group type: COMPARATOR
Intervention: Full-dose intramuscular jet injector (IM-JI-0.5)
Number of subjects: 125
Study 23770332 — intervention group
Group type: COMPARATOR
Intervention: Fractional-dose intramuscular needle (IM-NS-0.1)
Number of subjects: 125
Study 23770332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal jet injector (ID-JI-0.1)
Number of subjects: 125
Study 21991951 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg of teriflunomide
Number of subjects: 1088
Study 21991951 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg of teriflunomide
Number of subjects: 1088
Study 21991951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study 18774344 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted stop rule during ischemic pain task
Number of subjects: 61
Study 18774344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerance stop rule during ischemic pain task
Number of subjects: 61
Study 16930383 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year universal classroom-based intervention targeting disruptive behavior
Number of subjects: 508
Study 16930383 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 508
Study 14600055 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence coaching
Number of subjects: 286
Study 14600055 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 286
Study 14600055 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 286
Study 11076315 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanically guided percutaneous transluminal myocardial laser revascularization
Number of subjects: 0
Study 11076315 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopically guided percutaneous transluminal myocardial laser revascularization
Number of subjects: 0
Study 8927880 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg retarded nifedipine + 25 mg atenolol
Number of subjects: 36
Study 8927880 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg retarded nifedipine + 50 mg atenolol
Number of subjects: 36
Study 8927880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1433548 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous embolization
Number of subjects: 119
Study 1433548 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation of the internal spermatic vein
Number of subjects: 119
Study 1433548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transinguinal simultaneous ligation of the internal and external spermatic veins
Number of subjects: 119
Study 4013826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandfly fever virus inoculation
Number of subjects: 9
Study 4013826 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 9
Study 31690089 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet‐based self‐help cognitive behavioral intervention
Number of subjects: 188
Study 31690089 — intervention group
Group type: COMPARATOR
Intervention: Attention‐only control group
Number of subjects: 188
Study 30887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble breath exercise
Number of subjects: 66
Study 30887592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 28489506 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital intubation
Number of subjects: 882
Study 28489506 — intervention group
Group type: COMPARATOR
Intervention: Air transport
Number of subjects: 882
Study 23846682 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB
Number of subjects: 194
Study 23846682 — intervention group
Group type: COMPARATOR
Intervention: No SLNB
Number of subjects: 194
Study 23826914 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (150 mg/day for 4 weeks)
Number of subjects: 20
Study 23826914 — intervention group
Group type: COMPARATOR
Intervention: Control (no polaprezinc treatment)
Number of subjects: 20
Study 21739372 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside/toltrazuril suspension (at least 0.45 mg emodepside plus 9 mg toltrazuril per kg body weight)
Number of subjects: 403
Study 21739372 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside/toltrazuril suspension
Number of subjects: 403
Study 21739372 — intervention group
Group type: COMPARATOR
Intervention: Reference product (milbemycin oxime plus praziquantel or sulfadimethoxine)
Number of subjects: 403
Study 21739372 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 403
Study 20396715 — intervention group
Group type: EXPERIMENTAL
Intervention: Artrofoon treatment
Number of subjects: 0
Study 18163058 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 46
Study 15195037 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 39
Study 15195037 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail recruitment method
Number of subjects: 39
Study 15195037 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio advertisements recruitment method
Number of subjects: 39
Study 11471578 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (6 sessions, each lasting up to 25 minutes)
Number of subjects: 32
Study 11471578 — intervention group
Group type: COMPARATOR
Intervention: Advice and exercises
Number of subjects: 32
Study 11471578 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture vs Advice and exercises
Number of subjects: 32
Study 9649558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (Vit-C) supplementation with GTN
Number of subjects: 9
Study 9649558 — intervention group
Group type: COMPARATOR
Intervention: Glyceroltrinitrate (GTN)
Number of subjects: 9
Study 7925509 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase 30 units i.v. at home (early group)
Number of subjects: 311
Study 7925509 — intervention group
Group type: COMPARATOR
Intervention: Anistreplase 30 units i.v. in hospital (late group)
Number of subjects: 311
Study 2805811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulconazole nitrate 1 percent cream applied once daily
Number of subjects: 117
Study 2805811 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole applied twice daily
Number of subjects: 117
Study 171574 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 12
Study 171574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea and halofenate
Number of subjects: 12
Study 171574 — intervention group
Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 12
Study 31164288 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based pulmonary rehabilitation (PR) for 3 weeks plus standard medication
Number of subjects: 23
Study 31164288 — intervention group
Group type: COMPARATOR
Intervention: Standard medication
Number of subjects: 23
Study 30314830 — intervention group
Group type: EXPERIMENTAL
Intervention: Online decision aid (DA) during counseling
Number of subjects: 382
Study 30314830 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control)
Number of subjects: 382
Study 30314830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DA and control groups
Number of subjects: 382
Study 28457562 — intervention group
Group type: EXPERIMENTAL
Intervention: Reveal LINQ™ ICM implantation in a procedure room
Number of subjects: 1420
Study 28457562 — intervention group
Group type: EXPERIMENTAL
Intervention: Reveal LINQ™ ICM implantation in an electrophysiology laboratory
Number of subjects: 1420
Study 28457562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring device repositioning
Number of subjects: 1420
Study 28457562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not requiring device repositioning
Number of subjects: 1420
Study 28457562 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AEs with device explantation
Number of subjects: 1420
Study 28457562 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AEs without device explantation
Number of subjects: 1420
Study 28457562 — intervention group
Group type: COMPARATOR
Intervention: Patients undergoing implantation in a procedure room
Number of subjects: 1420
Study 28457562 — intervention group
Group type: COMPARATOR
Intervention: Patients undergoing implantation in an electrophysiology laboratory
Number of subjects: 1420
Study 25512417 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg of eflornithine every 6 h for 14 days
Number of subjects: 25
Study 25512417 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg/kg of eflornithine every 6 h for 14 days
Number of subjects: 25
Study 25512417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages of eflornithine
Number of subjects: 25
Study 24205183 — intervention group
Group type: EXPERIMENTAL
Intervention: ART for >12 weeks
Number of subjects: 165
Study 24205183 — intervention group
Group type: COMPARATOR
Intervention: ART for ≤12 weeks
Number of subjects: 165
Study 21732833 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks
Number of subjects: 1148
Study 21732833 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks
Number of subjects: 1148
Study 21732833 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (300 mg) daily for up to 6 years (continuous isoniazid)
Number of subjects: 1148
Study 21732833 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid (300 mg) daily for 6 months (control group)
Number of subjects: 1148
Study 19467054 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDgel (Emdogain)
Number of subjects: 15